LOGIN
Eicosapentaenoic and docosahexaenoic acid supplementation in breast cancer patients
May 2014
Eicosapentaenoic and docosahexaenoic acid supplementation in breast cancer patients
Study Type:Randomized Trial
OE Level Evidence:1
Journal Level of Evidence:N/A
High-dose eicosapentaenoic acid and docosahexaenoic acid supplementation reduces bone resorption in postmenopausal breast cancer survivors on aromatase inhibitors: a pilot study
Nutr Cancer. 2014;66(1):68-76. doi: 10.1080/01635581.2014.847964. Epub 2013 Nov 25Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
38 postmenopausal women being treated with aromatase inhibitors for breast cancer were randomized in this trial to determine the effect of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) on bone turnover and resorption. Participants were treated with capsules of either EPA+DHA or placebo (7 capsules/day) for 3 months, after which they were analyzed for serum fatty acid composition, biom...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
The OE High Impact metric uses AI to determine the impact a study will have by considering the content of the article itself. Built using the latest advances of natural language processing techniques. OE High Impact predicts an article’s future number of citations than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.